#1 Clinical Trials Search in Europe

Camonsertib

Camonsertib, also known as RP-3500, is an investigational drug being studied in clinical trials for the treatment of advanced solid tumors. This article summarizes key information about ongoing clinical trials evaluating Camonsertib alone and in combination with other therapies in patients with various types of advanced cancers.

Table of Contents

What is Camonsertib?

Camonsertib, also known as RP-3500, is a new drug being studied for the treatment of various types of cancer[1]. It belongs to a class of medications called ATR inhibitors, which work by targeting a specific protein in cancer cells[2]. This drug is still in the experimental stage and is being tested in clinical trials to determine its safety and effectiveness in treating cancer patients.

How Does Camonsertib Work?

Camonsertib works by inhibiting (blocking) a protein called ATR (Ataxia Telangiectasia and Rad3-related protein)[2]. This protein plays a crucial role in helping cancer cells repair their DNA when it’s damaged. By blocking ATR, Camonsertib makes it harder for cancer cells to survive and multiply, potentially slowing down or stopping tumor growth.

What Cancers Does Camonsertib Treat?

Camonsertib is being studied for the treatment of various types of advanced solid tumors[1]. Solid tumors are abnormal masses of tissue that don’t contain cysts or liquid areas. They can occur in many parts of the body, such as the lungs, breast, colon, and other organs. The clinical trials are focusing on patients whose tumors have specific genetic mutations that make them more likely to respond to ATR inhibitors like Camonsertib[3].

How is Camonsertib Administered?

Camonsertib is taken orally (by mouth) in the form of tablets or capsules[2]. In clinical trials, it is typically given on a specific schedule, such as on days 1-3 and days 8-10 of a 21-day cycle[4]. This means patients take the medication for three days, then have a break for four days, then take it for another three days, followed by a longer break before starting the next cycle.

Clinical Trials Involving Camonsertib

Several clinical trials are currently underway to study Camonsertib:

  • A Phase 1/2 study is testing Camonsertib alone and in combination with other cancer drugs like talazoparib (a PARP inhibitor) or gemcitabine in patients with advanced solid tumors[2].
  • Another study is looking at Camonsertib in combination with niraparib or olaparib (both PARP inhibitors) in patients with advanced solid tumors[1].
  • Camonsertib is also being studied in combination with atezolizumab (an immunotherapy drug) in patients with non-small cell lung cancer[4].
These trials aim to determine the safe dose of Camonsertib, understand how it works in the body, and assess its effectiveness in treating various types of cancer.

Potential Side Effects

As Camonsertib is still in clinical trials, the full range of potential side effects is not yet known. However, like all cancer treatments, it may cause some side effects. The clinical trials are carefully monitoring patients for any adverse events (side effects) to ensure the safety of the drug[1][2]. Patients participating in these trials are closely monitored by healthcare professionals.

Future Prospects

Camonsertib shows promise as a potential new treatment for various types of cancer, especially those with specific genetic mutations. The ongoing clinical trials will help determine its effectiveness and safety. If successful, Camonsertib could provide a new option for patients with advanced solid tumors who may have limited treatment options[3].

Aspect Details
Drug Name Camonsertib (RP-3500)
Drug Class ATR inhibitor
Administration Oral
Cancer Types Studied Advanced solid tumors, including non-small cell lung cancer
Key Trial Objectives Assess safety, determine proper dosing, evaluate effectiveness
Combination Therapies Atezolizumab, Bevacizumab, PARP inhibitors (e.g. niraparib, olaparib)
Biomarkers of Interest ATM loss of function, SETD2 loss of function
Primary Outcome Measures Safety, tolerability, maximum tolerated dose, objective response rate
Secondary Outcome Measures Pharmacokinetics, duration of response, progression-free survival

FAQ

  • What is Camonsertib? Camonsertib (RP-3500) is an investigational drug that inhibits a protein called ATR, which is involved in DNA damage repair in cancer cells. It is being studied as a potential treatment for advanced solid tumors.
  • What types of cancer is Camonsertib being studied for? Camonsertib is being evaluated in clinical trials for patients with various types of advanced solid tumors, including non-small cell lung cancer and tumors with specific genetic mutations like ATM or SETD2 loss of function.
  • How is Camonsertib administered? In the clinical trials, Camonsertib is given orally (by mouth) on specific days of each treatment cycle. The exact dosing schedule varies between trials but often involves taking it on days 1-3 and 8-10 of a 21-day cycle.
  • What are some of the other drugs being studied in combination with Camonsertib? Some trials are evaluating Camonsertib in combination with other cancer drugs like atezolizumab (an immunotherapy drug) and bevacizumab (a targeted therapy that blocks blood vessel growth in tumors).
  • What are researchers hoping to learn from these Camonsertib clinical trials? The main goals are to determine the safety, proper dosing, and effectiveness of Camonsertib. Researchers are looking at how well it shrinks tumors, prevents cancer progression, and improves survival in patients with advanced cancers.

Ongoing Clinical Trials on Camonsertib

  • Study on the Safety of RP-6306 Alone or with RP-3500 or Debio 0123 for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark France The Netherlands Spain

  • Study on the Effectiveness and Safety of Atezolizumab and Drug Combination for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

  • Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium Denmark France Germany Italy Poland +2

Glossary

  • ATR inhibitor: A type of drug that blocks the ATR protein, which is involved in DNA damage repair in cancer cells. ATR inhibitors like Camonsertib aim to make cancer cells more vulnerable to damage.
  • Advanced solid tumor: A cancer that has spread from where it started to other areas of the body. Solid tumors are abnormal masses of tissue that don't contain cysts or liquid areas.
  • Maximum tolerated dose (MTD): The highest dose of a drug that does not cause unacceptable side effects. Determining the MTD is an important goal of early phase clinical trials.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent further dose increases or require a dose reduction.
  • Recommended Phase 2 dose (RP2D): The dose of a drug selected for further testing in Phase 2 clinical trials, based on safety and efficacy data from Phase 1 studies.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer treatment works by assessing changes in tumor size on imaging scans.
  • Biomarker: A measurable substance in the body that can indicate the presence of disease, infection, or environmental exposure. In cancer, biomarkers may help predict response to treatment.
  • Circulating tumor DNA (ctDNA): Small fragments of DNA released by tumor cells into the bloodstream. Analyzing ctDNA can provide information about genetic changes in a person's cancer.

References

  1. https://clinicaltrials.gov/study/NCT04972110
  2. https://clinicaltrials.gov/study/NCT04497116
  3. https://clinicaltrials.gov/study/NCT04589845
  4. https://clinicaltrials.gov/study/NCT03337698